What are the recommended treatment options for microvascular angina, including risk‑factor modification and pharmacologic therapy?

Treatment of Microvascular Angina

For microvascular angina, beta-blockers or calcium channel blockers should be initiated as first-line therapy, with ACE inhibitors added for patients with reduced coronary flow reserve, and ranolazine or trimetazidine considered as second-line agents when symptoms persist despite initial treatment. 1

Risk Factor Modification

Aggressive cardiovascular risk factor management forms the foundation of treatment and should be implemented immediately:

• Smoking cessation is mandatory for all patients who smoke 1
• Blood pressure control to target <130/80 mm Hg should be achieved 1
• Lipid management with high-intensity statin therapy is recommended for all patients, targeting LDL reduction and providing pleiotropic vascular benefits 1, 2, 3
• Weight reduction to achieve normal body mass index improves outcomes 1
• Diabetes management with strict glycemic control is essential 1
• Exercise training through structured cardiac rehabilitation programs enhances functional capacity 4

First-Line Pharmacologic Therapy

Beta-Blockers (Preferred Initial Agent)

Beta-blockers should be the first-line antianginal medication for most patients with microvascular angina due to their proven efficacy in symptom control and favorable safety profile 1, 2:

• Selective beta-1 antagonists (bisoprolol, metoprolol succinate, or nebivolol) are preferred 1
• Particularly effective in patients with reduced coronary flow reserve or elevated microvascular resistance 1
• Contraindicated in sick sinus syndrome or significant atrioventricular conduction disorders 1
• Use with caution in peripheral artery disease and chronic obstructive pulmonary disease 1

Calcium Channel Blockers (Alternative or Combination)

Calcium channel blockers represent either an alternative to beta-blockers or can be combined with them 1:

• For vasospastic component: Calcium channel blockers receive a Class I, Level A recommendation and may require unusually high doses (diltiazem up to 400-960 mg daily) 1
• Dihydropyridines (amlodipine) can be safely combined with beta-blockers 1
• Non-dihydropyridines (diltiazem, verapamil) should not be combined with ivabradine or used in patients with left ventricular dysfunction 1

ACE Inhibitors

ACE inhibitors should be added for patients with coronary microvascular dysfunction, particularly those with reduced coronary flow reserve 1, 2, 3:

• Receive a Class IIa, Level B recommendation for symptom control in endothelial dysfunction 1
• Combination of high-intensity statin with maximally tolerated ACE inhibitor improves coronary endothelial function, microvascular function, and symptoms 3
• Angiotensin receptor blockers can substitute if ACE inhibitors are not tolerated 2, 5

Second-Line and Adjunctive Therapy

Ranolazine

Ranolazine should be considered when symptoms persist despite beta-blockers and/or calcium channel blockers 1, 6:

• Particularly effective for microvascular angina and endothelial dysfunction 1, 6
• Can be used as add-on therapy or as part of initial treatment in selected patients 1
• Reasonable option in patients with low heart rate or blood pressure where rate-limiting agents are problematic 1
• Evidence shows inconsistent improvements in Seattle Angina Questionnaire scores and coronary flow reserve 7

Trimetazidine

Trimetazidine may be considered as add-on therapy in patients with inadequate symptom control 1:

• Can be part of initial treatment in properly selected patients 1
• Reasonable option for combination therapy in patients with low heart rate or blood pressure 1

Long-Acting Nitrates

Long-acting nitrates should be considered as add-on therapy or when beta-blockers/calcium channel blockers are contraindicated 1:

• Must be used with a nitrate-free interval to avoid tolerance 1
• Patches should be dosed at least 10 mg 1, 8
• Contraindicated with phosphodiesterase inhibitors 1, 8
• Sublingual nitroglycerin should always be available for immediate symptom relief 1, 8

Ivabradine

Ivabradine is reserved for specific situations 1:

• Should be considered in patients in sinus rhythm who cannot tolerate beta-blockers 1
• Not recommended as add-on therapy in patients with ejection fraction >40% and no clinical heart failure 1
• Cannot be combined with non-dihydropyridine calcium channel blockers 1

Nicorandil

Nicorandil may be considered as add-on therapy, though safety data in heart failure are uncertain 1:

• Can be used when beta-blockers/calcium channel blockers are contraindicated or poorly tolerated 1

Antiplatelet and Preventive Therapy

• Aspirin 75-300 mg daily should be prescribed for all patients unless contraindicated 1
• Clopidogrel can substitute when aspirin is absolutely contraindicated 1

Treatment Algorithm

Step 1: Initiate beta-blocker (or calcium channel blocker if beta-blocker contraindicated) + ACE inhibitor + high-intensity statin + aspirin 1, 3

Step 2: If symptoms persist, add dihydropyridine calcium channel blocker to beta-blocker (avoid combining non-dihydropyridine calcium channel blockers with beta-blockers due to bradycardia risk) 1

Step 3: If symptoms remain inadequately controlled, add ranolazine, trimetazidine, or long-acting nitrates 1

Step 4: For refractory symptoms despite maximal medical therapy, consider coronary sinus reducer (Class IIb, Level B recommendation) 9

Critical Pitfalls to Avoid

• Do not combine ivabradine with non-dihydropyridine calcium channel blockers or strong CYP3A4 inhibitors 1
• Do not combine beta-blockers with non-dihydropyridine calcium channel blockers without careful monitoring for bradyarrhythmias 1
• Do not use nitrates with phosphodiesterase inhibitors (24 hours for sildenafil, 48 hours for tadalafil) 1, 8
• Do not abruptly discontinue beta-blockers; taper over four weeks 1
• Do not use immediate-release or short-acting dihydropyridine calcium antagonists as they increase adverse cardiac events 1

Monitoring and Follow-Up

• Ensure medication compliance and monitor for side effects 1
• Optimize dosing of one drug before adding another 1
• Consider invasive coronary function testing to guide therapy selection (Class IIa, Level A recommendation) 1
• Approximately 25-30% of patients remain refractory to intensive medical therapy and may require novel interventional approaches 2, 5